CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma

Zhang,Zhenhai; Qin,Chengkun; Wu,Yaguang; Su,Zhongxue; Xian,Guozhe; Hu,Bo

doi:10.3892/or.2014.2998

CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma

Authors:
- Zhenhai Zhang
- Chengkun Qin
- Yaguang Wu
- Zhongxue Su
- Guozhe Xian
- Bo Hu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Emergency, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: January 24, 2014 https://doi.org/10.3892/or.2014.2998
Pages: 1629-1636

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The chemokine receptor CCR9 was recently implicated in tumor biology. In the present study, our objective was to evaluate the clinical significance and potential role of CCR9 in hepatocellular carcinoma (HCC). CCR9 expression was detected by immunohistochemistry, quantitative PCR (qPCR) and western blotting in HCC patients. The prognostic significance of CCR9 expression was assessed. The functional roles of CCR9 in HCC were investigated using MTT, BrdU, colony formation assay and flow cytometry. CCR9 was significantly elevated in HCC tissue samples. High CCR9 expression was correlated with multiple tumor nodes, high Edmondson-Steiner grade and vascular invasion. Multivariate analysis showed that CCR9 expression was an independent prognostic factor for the overall survival (OS) of HCC patients. Further investigations revealed that ectopic expression of CCR9 enhanced cell proliferation and tumorigenicity in HCC cells, whereas CCR9 silencing impaired cell proliferation and tumorigenicity, which was mediated through downregulation of the cell cycle regulators p21, p27 as well as upregulation of cyclin D1. These results suggest that CCR9 can act as a novel prognostic marker and therapeutic target for HCC.

View Figures

View References

1	Zhu AX, Duda DG, Sahani DV and Jain RK: HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 8:292–301. 2011. View Article : Google Scholar : PubMed/NCBI
2	Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A and Montalto G: Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 3:236–260. 2012.PubMed/NCBI
3	McClune AC and Tong MJ: Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 14:461–476. 2010. View Article : Google Scholar : PubMed/NCBI
4	Finn RS: Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis. 33(Suppl 1): S11–S19. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 12:1175–1181. 2006.PubMed/NCBI
6	Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V and Dimitriadis G: Pathways and targets in hepatocellular carcinoma. Expert Rev Anticancer Ther. 12:1347–1357. 2012. View Article : Google Scholar : PubMed/NCBI
7	Viola A and Luster AD: Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 48:171–197. 2008. View Article : Google Scholar : PubMed/NCBI
8	Franciszkiewicz K, Boissonnas A, Boutet M, Combadière C and Mami-Chouaib F: Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 72:6325–6332. 2012. View Article : Google Scholar : PubMed/NCBI
9	Svensson M and Agace WW: Role of CCL25/CCR9 in immune homeostasis and disease. Expert Rev Clin Immunol. 2:759–773. 2006. View Article : Google Scholar : PubMed/NCBI
10	Shen X, Mailey B, Ellenhorn JD, Chu PG, Lowy AM and Kim J: CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg. 13:1955–1962. 2009. View Article : Google Scholar : PubMed/NCBI
11	Johnson-Holiday C, Singh R, Johnson E, et al: CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 38:1279–1285. 2011.
12	Geisler SA, Olshan AF, Weissler MC, et al: p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res. 8:3445–3453. 2000.PubMed/NCBI
13	Fukuoka J, Fuji T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 10:4314–4324. 2004. View Article : Google Scholar : PubMed/NCBI
14	Cao Z, Zhang R, Li J, et al: X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis. J Biol Chem. 288:20238–20247. 2013. View Article : Google Scholar
15	Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 9:416–423. 2003. View Article : Google Scholar
16	Yu Y, Kovacevic Z and Richardson DR: Tuning cell cycle regulation with an iron key. Cell Cycle. 6:1982–1994. 2007. View Article : Google Scholar : PubMed/NCBI
17	Macaluso M, Montanari M, Cinti C and Giordano A: Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 32:452–457. 2005. View Article : Google Scholar : PubMed/NCBI
18	Nakamoto N, Ebinuma H, Kanai T, et al: CCR9⁺ macrophages are required for acute liver inflammation in mouse models of hepatitis. Gastroenterology. 142:366–376. 2012.
19	Chu PS, Nakamoto N, Ebinuma H, et al: C-C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice. Hepatology. 58:337–350. 2013. View Article : Google Scholar : PubMed/NCBI
20	Amersi FF, Terando AM, Goto Y, et al: Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res. 14:638–645. 2008. View Article : Google Scholar : PubMed/NCBI
21	Johnson EL, Singh R, Singh S, et al: CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 8:622010. View Article : Google Scholar : PubMed/NCBI
22	Singh S, Singh UP, Stiles JK, Grizzle WE and Lillard JW Jr: Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 10:8743–8750. 2004. View Article : Google Scholar : PubMed/NCBI